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The aim of the present study was to evaluate the effect of leucine treatment (0.30mM)
on muscle weight and signaling of myoproteins related to synthesis and degradation
pathways of soleus muscle following seven days of complete sciatic nerve lesion. Wistar
rats (n = 24) of 3–4 months of age (192 ± 23 g) were used. The animals were randomly
distributed into four experimental groups (n = 6/group): control, treated with leucine
(L), denervated (D) and denervated treated with leucine (DL). Dependent measures were
proteins levels of AKT, AMPK, mTOR, and ACC performed by Western blot. Leucine
induced a reduction in the phosphorylation of AMPK (p < 0.05) by 16% in the L and by
68% in the DL groups as compared with control group. Denervation increased AMPK
by 24% in the D group as compared with the control group (p < 0.05). AKT was
also modulated by denervation and leucine treatment, highlighted by the elevation of
AKT phosphorylation in the D (65%), L (98%) and DL (146%) groups as compared
with the control group (p < 0.05). AKT phosphorylation was 49% higher in the D
group as compared with the DL group.Furthermore, denervation decreased mTOR
phosphorylation by 29% in the D group as compared with the control group. However,
leucine treatment induced an increase of 49% in the phosphorylation of mTOR in the
L group as compared with the control group, and an increase of 154% in the DL as
compared with the D group (p < 0.05). ACC phosphorylation was 20% greater in the D
group than the control group. Furthermore, ACC in the soleus was 22% lower in the in
the L group and 50% lower in the DL group than the respective control group (p < 0.05).
In conclusion, leucine treatment minimized the deleterious effects of denervation on
rat soleus muscle by increasing anabolic (AKT and mTOR) and decreasing catabolic
(AMPK) pathways. These results may be interesting for muscle recovery following acute
denervation, which may contribute to musculoskeletal rehabilitation after denervation.
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Introduction
Peripheral nerve injuries are commonly present during clinical
practice of orthopedics and traumatology,in which alterations of
the functional pattern of peripheral and central nervous system
are accompanied by muscle tissue disuse. In case of total inter-
ruption of motor innervation, there is an immediate loss of tissue
voluntary and reflex action, intramuscular proliferation of con-
nective tissue, and decrease or loss of muscle force generating
capacity (Reardon et al., 2001; Dow et al., 2006; Durigan et al.,
2014).
During denervation there is an increase of muscle proteins
related to proteolysis, such as atrogin-1/MAFbx and MuRF1
(Muscle RING Finger 1), as well as the reduction in the expres-
sion of proteins related to protein synthesis, such as AKT/mTOR
(serine/threonine-specific protein kinase and Mammalian Target
of Rapamycin, respectively), which in turns modulate the 4EBP1
p70S6K1 (Bodine et al., 2001; Lima et al., 2007; Salvini et al.,
2012; Bonaldo and Sandri, 2013). AMP-activated protein kinase
(AMPK), a sensor of cellular energy status, was recently shown to
increase myofibrillar protein degradation and autophagy through
the expression of MAFbx and MuRF1 (Sanchez et al., 2012).
Consequently, skeletal muscle undergoes in a harmful nutri-
tion status with modification of acetyl-CoA carboxylase (ACC)
activity (Han et al., 2007), as well as a peripheral insulin resis-
tance due to the decrease of phosphatidylinositol 3-kinase (PI3K)
levels, which is linked to the insulin receptor and the reduction of
glucose transporters (GLUTs). This process results in the decrease
of energetic reserves and muscle proteolysis (Coderre et al., 1992;
Bodine et al., 2001; Salvini et al., 2012; Bonaldo and Sandri, 2013).
Some substances have been used as a therapeutic strategy to
minimize denervation induced atrophy, such as branched-chain
amino acids (BCAAs), especially leucine (Kelleher et al., 2013). It
was demonstrated that the use of leucine-enriched high protein
diet do not protect soleus single fiber characteristics (fiber size
and contractile function) after 60-day bed rest in humans. The
divergent response in size and functional MHC I soleus proper-
ties with the concurrent exercise program was a unique finding
further highlighting the challenges of protecting the unloaded
soleus, maintaing MHC power but not size and strength (Trappe
et al., 2008).Mounier et al. (2009) also demonstrate that the nutri-
tion of proteins and BCAAs countermeasure was more specif-
ically efficient against slow fiber atrophy assessed by western
blotting and force of single skinned fibers after a 60-day bed rest.
It has been shown that BCAA prevents dexamethasone-
induced muscle atrophy in rats (Yamamoto et al., 2010). Other
studies have shown that BCAA inhibited atrogin-1 and MuRF1
expression in the C2C12 mouse muscle cell line (Xu et al., 2001;
Shimomura et al., 2006; Herningtyas et al., 2008; Yamamoto et al.,
2010), andminimized themuscle atrophy in rats that were immo-
bilized for 7 weeks (Xu et al., 2001; Shimomura et al., 2006; Hern-
ingtyas et al., 2008; Yamamoto et al., 2010; Kelleher et al., 2013).
In addition, leucine treatment can attenuate the loss of lean mass,
improve tissue repair andmuscle protein turnover in elderly indi-
viduals, and induce beneficial effects for the treatment of liver
and kidney diseases (Norton and Layman, 2006; Maki et al., 2012;
Kelleher et al., 2013).
Taking together, these findings suggest that BCAA may
protect against muscle atrophy by inhibiting protein breakdown
as well as protein synthesis. However, the effects of leucine on
the atrophy process and correlated signaling pathways during the
acute phase of denervation are not known. Thus, we aimed to
evaluate the effects of leucine treatment on muscle weight and
signaling for synthesis and degradation of myoproteins in the
soleus muscle of rats following total injury of the sciatic nerve.
We hypothesized that leucine treatment would minimize the
deleterious effects of denervation in the soleus muscle.
Methods
Wistar rats (n = 24) of 3–4 months of age (192 ± 23 g) were
used. The animals housed in collective polypropylene cages in a
room with controlled temperature ranging (22–27◦C) on a 12 h
light/dark cycle and had free access to water and a balanced
diet with standard rodent chow (Purina, Descalvado-São Paulo,
Brazil). The animal experiments described here were approved by
the Institutional Committee for Ethics in Animal Experimenta-
tion (protocol n 011/2006) and were done in accordance with the
guidelines of the Brazilian College for Animal Experimentation
(COBEA).
The animals were randomly distributed into four experimen-
tal groups (n = 6/group): control, treated with leucine (L), den-
ervated (D) and denervated treated with leucine (DL). Both the
period of denervation and treatment lasted 7 days. Leucine was
delivered with doses of 0.30mM/100 g (Sigma St. Louis, MO,
USA) introduced into the digestive system via an orogastric flex-
ible tube. A dose-response curve based in a previous study of
our laboratory revealed that 0.30mM was effective in maintain-
ing muscle glycogen content after denervation. After anesthesia
with sodium tiopental (40mg/kg body weight, ip), muscles were
denervated by surgical removal of 1 cm of sciatic nerve from left
posterior hindlimb (Coderre et al., 1992).
Following 7 days of treatment, the animals were anesthetized
in a CO2 chamber and euthanized. The soleus muscle was rapidly
removed, washed in saline solution, weighted and mixed to an
extraction buffer, as follow: (100mMTrisma base, pH 7.5, 10mM
EDTA, 100mM sodium pyrophosphate, 100mM NaF, 10mM
Na3VO4, 2mM PMSF diluted in ethylic alcohol, 1% Triton X-
100 and 0.1mg/ml aprotinine), at 4◦C in a Polytron PTA 20S
homogenizer (model PT 10/35; Brinkmann Instruments, West-
bury, NY) at maximal velocity for 30 s. The cell fragments were
centrifuged (15.500 × g, 20minutes, 4◦C) for the removal of the
insoluble material, and the supenatant was used for the assay.
Part of the material was used for the determination of total pro-
tein content by the Biuret photo colorimetric method (Bradford),
while the remaining material was used for Western Blot analy-
sis. The reagents for the determination of total protein content
(Biuret), SDS/PAGE andWestern Blot were from Bio-Rad (Rich-
mond, CA, USA). Nitrocellulose membranes were from Amer-
sham Corp. (Aylesbury, UK). The chemiluminescence kit was
obtained from Endogen (Rockford, IL). All other materials were
obtained from Sigma (St. Louis, MO, USA).
After the measurement of total protein content, a buffer con-
taining 100mM of dithiothreitol was added to the supernatant,
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and then heated for 5–10min. Equal quantities of proteins
(75µg) were submitted to eletroforesis in poliacrilamide
SDS-PAGE gels at the BIO-RAD miniature slab gel appa-
ratus (Mini-Protean, Bio-Rad Laboratories, Richmond, CA).
The electrotransfer of gel proteins to the membrane lasted
120min at 120V in a miniaturized transference device (BIO-
RAD). The binding of the antibodies to non-specific pro-
teins was reduced by the pre-incubation of the membrane
with blocking buffer under room temperature (5% BSA dis-
solved in basal solution) to 120min. The nitrocelulose mem-
brane was incubated, overnight, with specific antibodies:
anti-pSer473AKT (#4058), anti-pAMPK (#2537), anti-pmTOR
(#2971), and anti-pACC (#3661) obtained from Cell Signaling
Technology (Beverly, MA), diluted in antibody solution (3%
BSA); and then washed for 15min with basal solution (150mM
NaCl, 10mM Trisma base and 0.02% of Tween 20). Detec-
tion of the antigen-antibody complex attached to the nitro-
celulose membrane was determined via chemiluminescence by
using a commercial kit from Amersham and following rec-
ommendations from the manufacturer. β-Actin was used as
the internal control. Following the revelation of the auto-
radiographs, the identified bands were quantified by optical
densitometry.
Statistical Analysis
All variables showed normal distribution (Shapiro–Wilk test) and
homoscedasticity (Levene test). Thus, Two-WayANOVA (dener-
vation x treatment) followed by the Tukey multiple paired analy-
sis was used for comparisons among treatments. Differences were
considered significant when P < 0.05. All data were analyzed
using the Statistica 7.0 software package (StatSoft Inc., Tulsa, OK,
USA).
Results
There were group × time interactions showing that denervation
and leucine treatment interact with muscle weight (p < 0.05).
Denervation decreased soleus muscle weight by 35.1% as com-
pared with the control group (p < 0.05). Leucine treatment min-
imized muscle weight loss by 28% in the DL group as compared
with the D group (p < 0.05). Moreover, soleus muscle weight was
TABLE 1 | Soleus muscle mass/body mass ratio (MM/BM) in the control
group (C), treated with leucine (L), denervated (D), and denervated treated
with leucine (DL).
Groups MM/BM
C 0.55 ± 0.01
L 0.65 ± 0.01*
D 0.36 ± 0.04*
DL 0.46 ± 0.008*#∼
Values are mean ± standard error of the mean (SEM), n = 6. *p < 0.05 compared to C,
#p < 0.05 compared to D; ∼p < 0.05 compared to L.
17.5% greater in the L group than the control group (p < 0.05;
Table 1).
There were group × time interactions showing that
denervation and leucine treatment interact with to the AMPK,
AKT, mTOR, and ACC proteins level. Leucine induced a reduc-
tion in the phosphorylation of AMPK (p < 0.05) by 16% in
the L and by 68% in the DL groups as compared with control
group. Denervation increased AMPK by 24% in the D group as
compared with the control group (p < 0.05; Figure 1). AKT
was also modulated by denervation and leucine treatment, high-
lighted by the elevation of AKT phosphorylation in the D (65%),
L (98%), and DL (146%) groups as compared with the control
group (p < 0.05). AKT phosphorylation was 49% higher in the
D group as compared with the DL group (Figure 2; p < 0.05).
Furthermore, denervation decreased mTOR phosphorylation
by 29% in the D group as compared with the control group.
However, leucine treatment induced an increase of 49% in the
phosphorylation of mTOR in the L group as compared with the
control group, and an increase of 154% in the DL as compared
with the D group (Figure 3; p < 0.05). ACC phosphorylation
was 20% greater in the D group than the control group. Further-
more, ACC in the soleus was 22% lower in the in the L group
and 50% lower in the DL group than the respective control group
(Figure 4; p < 0.05).
Discussion
To the best of our knowledge, this is the first study to investi-
gate the effects of leucine treatment following 7 days of denerva-
tion on the molecular pathways of muscle protein synthesis and
degradation of rats. The initial hypothesis was confirmed, since
leucine minimized the early deleterious effects of denervation on
the soleus muscle by increasing important molecular pathways
FIGURE 1 | AMPK protein phosphorylation in arbitrary unit (AU) in the
control group (C), treated with leucine (L), denervated (D), and
denervated treated with leucine (DL). Values are mean ± standard error of
the mean (SEM), n = 6. ∗p < 0.05 compared to C, #p < 0.05 compared to D;
∼p < 0.05 compared to L.
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FIGURE 2 | AKT protein phosphorylation in arbitrary unit (AU) in the
control group (C), treated with leucine (L), denervated (D), and
denervated treated with leucine (DL). Values are mean ± standard error of
the mean (SEM), n = 6. ∗p < 0.05 compared to C, #p < 0.05 compared to D;
∼p < 0.05 compared to L.
FIGURE 3 | mTOR protein phosphorylation in arbitrary unit (AU) in the
control group (C), treated with leucine (L), denervated (D), and
denervated treated with leucine (DL). Values are mean ± standard error of
the mean (SEM), n = 6. ∗p < 0.05 compared to C, #p < 0.05 compared to D;
∼p < 0.05 compared to L.
involved with muscle protein synthesis. Although this study was
performed in animals, it has clinical relevance and indicates the
importance of leucine treatment in the acute phase of muscle
atrophy with the attempt to reduce the deleterious effects related
to denervated muscles.
Leucine is known to regulate protein turnover of muscle cells,
inhibiting protein degradation and promoting protein synthesis
(Norton and Layman, 2006; Tom and Nair, 2006; Maki et al.,
2012; Kelleher et al., 2013). Among the possible mechanisms
involved, leucine can activate protein synthesis in the muscle,
heart, liver and kidney by mTOR-dependent pathways (mTOR,
FIGURE 4 | ACC protein phosphorylation in arbitrary unit (AU) in the
control group (C), treated with leucine (L), denervated (D), and
denervated treated with leucine (DL). Values are mean ± standard error of
the mean (SEM), n = 6. ∗p < 0.05 compared to C, #p < 0.05 compared to D.
S6K1, and 4E-BP1) and mTOR-independent pathways (Norton
and Layman, 2006). Moreover, it has been shown that the ability
of leucine to phosphorylate p70s6k (serine/threonine kinase that
acts downstream PI3-K pathway) is blocked by rapamycin, an
inhibitor of mTOR and phosphatidylinositol 3-kinase (PI3-K)
(Tom and Nair, 2006).
Escobar et al. (2006), found that leucine increases the phos-
phorylation of S6K1 and rpS6 in glycolytic muscles, such as the
type II myosin containing latissimus dorsi. Furthermore, the ele-
vation of plasma leucine induced an increase in the phosphory-
lation of 4E-BP1 at the Thr70, with a concomitant decrease of
4E-BP1 and eIF4E complex; and an increase of the eF4G complex
and IF4E in skeletal muscle (Escobar et al., 2006). Similarly, the
present study revealed that leucine treatment increased the phos-
phorylation of AKT, mTOR and reduced ACC in the soleus mus-
cle following 7 days of denervation, indicating the anti-catabolic
effect of leucine during denervation-induced atrophy.
Leucine also know to affect the autophagy-lysosome system.
Mordier et al. (2000) showed that leucine restriction induces the
formation of autophagy and activation of lysosomal-dependent
proteolysis in C2C12 myotube. Kadowaki and Kanazawa (2003)
suggest that leucine has direct regulatory potencial in liver
autophagic proteolysis. In addition, a reduction in muscle
mass was suppressed by leucine-supplementation (1,5% leucine)
in rats fed protein-free diet for 7 days. The results showed
that the expression of a very specific marker of autophagen,
microtubule-associated protein light chain 3 active form (LC3-
II) was significantly decreased, wherein atrogin-1 and MuRF1
were not suppressed. It is suggested that inhibition of autophagy-
lysossome is likely the system involved in the suppression of
myofibrillar protein degradation by leucine (Sugawara et al.,
2009).
Interestingly, our results revealed that denervation decreased
mTOR and increased AMPK and ACC, which are activated
during energy catabolism, such as decreased ATP levels. It
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has been proposed that p70s6k controls AMPK signaling
and affects intracellular energetic metabolism, represented
by the AMPK/ATP ratio. Although leucine may modu-
late the AMPK/ATP ratio and mTOR/p70s6k pathways, the
increase of AMPK phosphorylation may occur without a
relevant modification of muscle energy status (Deshmukh
et al., 2009; Iwanaka et al., 2010). This fact may explain
the reduction of mTOR signaling and consequently a reduc-
tion of muscle atrophy observed in denervated and treated
animals.
Futhermore, Filiputti et al. (2010) investigated the islet cells
of rats treated with different diets, and found that leucine treat-
ment increased mTOR activation by 2.5 times in a group with
diet restriction (composed of 6% of protein) and in the normal
diet group. Leucine treatment also minimized the decrease of
S6K-1 ribosomal protein induced by protein restriction. These
results indicate that the activation of PI-3K and mTOR induced
by leucine may be involved in insulin secretion during protein
restriction.
In the present study, denervation increased AMP-activated
protein kinase expression, indicating that the autophagy pro-
tein breakdown system may be involved in muscle atrophy
induced by denervation. Along this line, Sugawara et al. (2009)
showed that L-leucine reversed a reduction in gastrocnemius
muscle weight and reversed increased LC3II expression (an
autophagy marker) induced by a protein-free diet for 7 days
in rats. The difference between their study and ours is likely
due to the differences in the experimental methods. They
selected a protein-free diet for an induction of muscle atro-
phy, which markedly increases autophagy, while we demon-
strated, for the first time, the role of AMP-activated protein
kinase expression after denervation-induced atrophy. Our results
suggest that leucine treatment may protect muscle mass via
the autophagy pathway, and increasing AKT/mTOR signaling
pathways.
It is important to consider some limitations of the present
study. Movement restriction inherit to the denervation surgery
process could exert some influence on the results of the dener-
vation groups, possibly potentiating the effects of disuse atrophy,
especially during the first few days of denervation. Future stud-
ies should consider a follow up of animals to access pain and
movement restriction during the first days after the denervation
process and correlate these finds with muscle disuse adaptation.
Moreover, we have a limitation of AKT normalization in the
western blotting assay. This may explain the surprising increase
of AKT in the phosphorylated states of denervated muscles.
Future studies should also include non-phosphorylated forms to
normalize the phospho isoforms of AKT and also include differ-
ent AKT isoforms. Moreover, antiphosphatases inhibitors should
be used to prevent degradation of the phosphoisoforms of AKT
and mTOR. Muscle cross sectional area analysis should also be
included. The results revealed atrophy in the entire soleus mus-
cle, and selective atrophy on different types of muscle fibers could
be missed.
Conclusion
In conclusion, leucine treatment minimized the deleterious
effects of denervation on rat soleus muscle by increasing anabolic
(AKT and mTOR) and decreasing catabolic (AMPK) pathways.
These results may be interesting for muscle recovery follow-
ing acute denervation. Future studies investigating additional
molecular pathways, muscle function and morphology should be
conducted.
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